Why ASML Shares Fell 10% on China's DUV News and Why Three Major Banks Say the Threat Is Overblown

On July 27–28, 2026, ASML shares fell roughly 10% over two sessions, wiping about €60 billion in market value . The trigger was a report from The Information that a Shanghai-based, state-backed consortium (involving Huawei and SiCarrier) had begun mass-producing homegrown immersion DUV (deep ultraviolet) lithography tools . ASML fell as much as 6.6% on the first day and another ~4.8% on the second, dragging U.S. peers Applied Materials, Lam Research, and KLA Corp lower as well .

The market reaction reflects that China accounted for roughly 14–20% of ASML's recent revenue, and DUV immersion tools are a meaningful slice of those sales . A credible domestic competitor — even at very early stages — raises the question of whether ASML's monopoly in DUV lithography is eroding.

How the Three Banks Analyzed the Threat

Bank of America

BofA called the sell-off an "overreaction" and reiterated its Buy rating with a $2,845 price target on ASML's U.S.-listed shares .

• Production volumes: The Chinese consortium plans 5 immersion DUV units in 2026 and roughly 20 in 2027 . By contrast, ASML shipped 131 such systems in 2025 alone, and plans ~130 immersion DUV units in 2026 with a 30% increase planned for 2027 . The Chinese output is infinitesimal relative to ASML's scale.
• Revenue impact: BofA assessed China as only a "modest threat" that is unlikely to materially affect ASML's near-term revenue . Even if China scales to 20 units in 2027, BofA estimates the maximum annual revenue impact at about €1.4 billion, or roughly 2.4% of group sales .
• Technological gap: The Chinese systems still lag significantly in performance, precision (resolution/node capability), throughput (wafer output per hour), and reliability. They need further testing and are not yet at production-grade quality .
• Broader outlook: BofA argued that ASML's true competitive fortress is EUV (extreme ultraviolet) lithography, which China is legally barred from accessing under export controls. The bank said investors were reading too much into trade press coverage .

JPMorgan

On this specific sell-off, JPMorgan's detailed post-report assessment is not as widely cited as BofA's, but the bank's broader view came through in earlier and related coverage.

• Production volumes: JPMorgan acknowledged the same headline figures — 5 units in 2026 and ~20 in 2027 — and noted they are negligible versus ASML's output .
• Revenue impact: In an earlier note (April 2026), JPMorgan had warned that potential U.S. export restrictions on DUV tools to China could reduce ASML's sales and earnings per share by several percentage points, but the Chinese domestic replacement threat was seen as much smaller .
• Technological gap: JPMorgan's analysts described the Chinese tools as having "far to go to match ASML's" performance and reliability . The systems still trail on overlay accuracy, resolution, and manufacturing yields.
• Broader outlook: JPMorgan characterized the development as "another data point in China's equipment self-sufficiency story" that raises legitimate long-term questions but does not threaten ASML's dominance in the near-to-medium term .

BNP Paribas

BNP Paribas joined BofA and JPMorgan in describing the sell-off as excessive, citing four structural reasons .

• Production volumes: BNP highlighted the same massive production disparity — 5 Chinese units in 2026 versus ASML's ~130 — as the primary reason the threat is overstated .
• Revenue impact: The bank assessed that even if China scales to 20 units in 2027, this represents a tiny fraction of ASML's DUV revenue stream and is unlikely to be material .
• Technological gap: BNP emphasized that the Chinese systems face enormous challenges in precision, throughput, and lithography resolution. Even the immersion DUV systems they are copying require years of iterative refinement to approach ASML's standards. The bank also noted that ASML's most advanced systems use proprietary technology and supply chains that China cannot easily replicate .
• Broader outlook: BNP Paribas concluded that the competitive moat remains intact. The Chinese push is a long-term strategic factor to monitor, but not a near-term earnings risk .

Summary Table

Factor	BofA	JPMorgan	BNP Paribas
Rating / Stance	Buy, $2,845 PT, sell-off is "overreaction"	Cautious but sees limited near-term threat	Sell-off excessive, moat intact
China production (2026/27)	~5 / ~20 units	Same figures, negligible vs. ASML	~5 / ~20, tiny relative to ASML's ~130
Revenue impact	Modest threat, no material near-term impact; max €1.4B (2.4% of sales)	Minimal from domestic replacement; bigger risk from U.S. export curbs	Not material at current scale
Technological gap	Significant lag in precision, throughput, reliability	"Far to go to match ASML"	Huge gap in precision, throughput, supply chain
Key differentiator	EUV monopoly is the true moat; China can't access it	Long-term self-sufficiency story, not near-term risk	Proprietary tech and supply chains are hard to replicate

Bottom line: All three banks see the Chinese DUV breakthrough as real but dramatically overhyped by the market. The consensus is that the reported volumes are a rounding error compared to ASML's production scale, the technological gap remains wide, and ASML's EUV monopoly — which China cannot legally access — provides a structural moat that DUV competition alone cannot breach.